Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”

z-VAD-fmk decreases 3D7 <i>P. falciparum</i> CQ sensitivity. by Benoît Meslin (209326)

Dose-dependent decreases in cell viability with carboplatin, mitoxantrone, vinblastine, and CBD treatment of canine UC cells. by Jordon M. Inkol (11237604)

Root Mean Square Error (RMSE) decreases with number of structures used. by Samuel Coulbourn Flores (11636717)

Summary plot for the effect of important food sources of fructose-containing sugars on systolic blood pressure (SBP). by Qi Liu (33068)

sEH inhibition decreased 16-week HF-diet–induced activation of inflammatory pathways in the liver. by Yan Liu (25061)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on early cytokine response after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

IL-1Ra treatment decreases activity and increases rest time in <i>mdx</i> mice. by Margaret E. Benny Klimek (2805361)

“…(n = 6 saline, n = 10 IL-1Ra).</p>…”

Fixation becomes unlikely with decreasing fitness of mutant homozygotes, variance in allele frequency increases with migration rate. by Philipp M. Altrock (340203)

Adding AGPAT2 and DGKα to CHO-GPAT1 cells decreased PPARγ activity. by Cliona M. Stapleton (352965)

LY411,575 decreases infection of hepatic cells by <i>P. berghei</i> ANKA sporozoites. by Iana Parvanova (12738)

MxB decreases the nuclear γH2AX foci induced by L1 retrotransposition. by Yu Huang (15093)

H₂O₂ decreases podocyte expression of SD molecules. by Xiqian Lan (219539)

Decreased apoptotic cell death in H9c2 cells treated with OA (caspase activity). by Rudo F. Mapanga (302485)

CNS-<i>Actb</i>KO mice exhibited hyperactivity and decreased performance in the Morris water maze. by Thomas R. Cheever (226943)

<i>Syx5</i> suppression in <i>Drosophila</i> S2 cells decreases copper accumulation. by Melanie Norgate (234832)

Sustained and repetitive HQ-induced oxidative injury decreases on MCP-1 expression in human RPE cells. by Marianne Pons (355277)